Donepezil exerted slight unfavorable effects on the musculoskeletal system in rats

Londzin, Piotr; Trawczyński, Marcin; Cegieła, Urszula; Folwarczna, Joanna

doi:10.1016/j.bonr.2022.101467

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy is a study indicating a higher likelihood of early-onset AD in males treated with memantine, whereas females were more linked to late-onset AD (Miller et al, 2022), which this divergence in association could possibly stem from sex-related differences in the effectiveness of memantine treatment. However, understanding the precise mechanism requires further investigation and worth noting is memantine's potential slightly negative impact on female rat skeletal health relative to males (Londzin et al, 2023). Interestingly, during the prodromal stages of AD, treatment with rivastigmine has been observed to delay the progression from MCI to AD in women, but not in men.…”

Section: Cholinesterase Inhibitors and Anti-nmdamentioning

confidence: 99%

Sex differences in the relationship between depression and Alzheimer’s disease—mechanisms, genetics, and therapeutic opportunities

Chen,

Wang,

Liu

et al. 2024

Front. Aging Neurosci.

View full text Add to dashboard Cite

Depression and Alzheimer’s disease (AD) are prevalent neuropsychiatric disorders with intriguing epidemiological overlaps. Their interrelation has recently garnered widespread attention. Empirical evidence indicates that depressive disorders significantly contribute to AD risk, and approximately a quarter of AD patients have comorbid major depressive disorder, which underscores the bidirectional link between AD and depression. A growing body of evidence substantiates pervasive sex differences in both AD and depression: both conditions exhibit a higher incidence among women than among men. However, the available literature on this topic is somewhat fragmented, with no comprehensive review that delineates sex disparities in the depression–AD correlation. In this review, we bridge these gaps by summarizing recent progress in understanding sex-based differences in mechanisms, genetics, and therapeutic prospects for depression and AD. Additionally, we outline key challenges in the field, holding potential for improving treatment precision and efficacy tailored to male and female patients’ distinct needs.

show abstract

Section: Cholinesterase Inhibitors and Anti-nmdamentioning

confidence: 99%